ABCC1 and neoplasm: The lack of significant and prolonged reduction in growth and viability of the model following exposure to irinotecan, with complete recovery after cessation of the treatment, supports the resistance of the mini-tumor model to MRP1-substrate chemotherapeutic drugs.